Cellular Mechanisms of Epithelial Mechanosensation in Chronic Upper-Airway Dysfunction

Abstract

Chronic upper-airway dysfunction encompasses a spectrum of clinical entities such as chronic rhinosinusitis, allergic rhinitis, and obstructive sleep apnea, all of which are increasingly recognized for their significant burden on global health. Recent advances have focused on the epithelial lining of the upper airway as a dynamic interface integral to immune surveillance and mechanosensation. This article reviews the current understanding of cellular and molecular mechanisms underlying epithelial mechanosensation, their contribution to chronic upper-airway pathology, and the implications for diagnosis, risk stratification, and personalized therapeutic interventions. Emphasis is placed on the interplay between mechanical stimuli, epithelial cell signaling, and downstream inflammatory and remodeling processes.

Introduction

Chronic upper-airway dysfunction (CUAD) represents a major clinical challenge, affecting a substantial proportion of the population worldwide and resulting in reduced quality of life, increased healthcare utilization, and significant economic impact. While the pathogenesis of CUAD is multifactorial, recent evidence highlights the pivotal role of airway epithelial cells not only as passive barriers but also as active sensors of mechanical and chemical stimuli. These cells orchestrate immune responses and tissue remodeling through complex mechanosensory pathways. Understanding these pathways is crucial for clinicians and researchers aiming to develop targeted therapies that address the foundational cellular mechanisms driving chronic airway dysfunction.

Epidemiology / Disease Burden

The prevalence of chronic upper-airway disorders such as chronic rhinosinusitis and allergic rhinitis is estimated at over 10% in adult populations globally, with obstructive sleep apnea affecting up to 20% of certain demographics. These conditions are associated with significant morbidity, including impaired sleep, cognitive deficits, and heightened cardiovascular risk. Direct and indirect healthcare costs are substantial, with millions of physician visits, surgical interventions, and lost workdays annually, underscoring the imperative for improved mechanistic understanding and management.

Pathophysiology

The airway epithelium forms a critical barrier, exposed constantly to environmental changes, pathogens, and mechanical forces such as airflow and particulate deposition. Mechanosensation in epithelial cells is primarily mediated through specialized ion channels (e.g., Piezo1, Piezo2, TRPV4), integrins, and cytoskeletal elements. Upon mechanical stimulation, these sensors transduce physical forces into intracellular biochemical signals, modulating gene expression, cytokine release, and epithelial permeability. In CUAD, dysregulation of mechanosensory signaling leads to aberrant activation of downstream pathways such as NF-κB, TGF-β, and YAP/TAZ, promoting chronic inflammation, mucosal remodeling, and impaired mucociliary clearance. Emerging data also implicate crosstalk with immune cells, particularly innate lymphoid cells and dendritic cells, in amplifying disease activity.

Risk Factors

Genetic predisposition, environmental exposures (pollutants, allergens), recurrent infections, and anatomical variations (e.g., septal deviation, turbinate hypertrophy) contribute to CUAD risk. Disruption of normal epithelial mechanosensation, whether due to inherited channelopathies or acquired damage from irritants, increases susceptibility to chronic inflammation and tissue remodeling. Occupational factors, smoking, and comorbidities such as asthma further augment risk by perpetuating epithelial dysfunction and inappropriate mechanotransduction.

Clinical Features

Patients with chronic upper-airway dysfunction present with persistent nasal congestion, rhinorrhea, cough, hyposmia, sneezing, and, in some cases, sleep disturbances and daytime fatigue. Physical examination may reveal mucosal edema, polyps, and evidence of chronic inflammation. In severe cases, complications such as sinusitis, otitis media, or lower airway involvement may arise, reflecting the systemic implications of epithelial barrier compromise and mechanosensory dysfunction.

Diagnosis

Diagnosis of CUAD incorporates detailed history, nasal endoscopy, imaging (CT or MRI), and functional assessments, including rhinomanometry and olfactory testing. Recent advances enable the evaluation of epithelial biomarkers (e.g., periostin, TSLP, IL-33) and, in research settings, the assessment of mechanosensory channel expression via nasal brushings or biopsies. Identification of epithelial barrier defects and mechanosensory dysfunction can inform prognosis and guide individualized management.

Treatment & Management

Management strategies for CUAD focus on reducing inflammation, restoring epithelial function, and alleviating symptoms. Standard therapies include topical and systemic corticosteroids, saline irrigation, antihistamines, leukotriene modifiers, and, in select cases, surgical intervention to address anatomical contributors. Restoration of healthy mechanosensation is an emerging therapeutic goal, with interventions aimed at stabilizing epithelial barriers, modulating mechanosensitive signaling, and preventing maladaptive tissue remodeling. Patient education and control of environmental exposures remain cornerstone strategies.

Recent Advances / Emerging Therapies

Recent translational research highlights the targeting of epithelial mechanosensory channels as a novel therapeutic approach. Small molecule modulators of Piezo and TRP channels are under investigation for their ability to restore normal mechanotransduction and reduce pathological inflammation. Biologics directed against epithelial-derived cytokines (e.g., anti-TSLP, anti-IL-33) have demonstrated efficacy in reducing exacerbations and improving control in refractory cases. Advances in single-cell sequencing and organ-on-chip models are elucidating cell-specific responses to mechanical stress, paving the way for personalized medicine in CUAD.

Guideline Recommendations

Current clinical guidelines from organizations such as the European Academy of Allergy and Clinical Immunology and the American Academy of Otolaryngology emphasize a multidisciplinary approach to CUAD, integrating symptom assessment, objective testing, and targeted therapies. Recommendations increasingly recognize the importance of epithelial health and advocate for research into biomarkers and mechanism-driven interventions. Early identification and management of at-risk individuals, along with adoption of emerging therapies as evidence evolves, are key strategies endorsed by expert panels.

Conclusion

Advancements in understanding the cellular mechanisms of epithelial mechanosensation are transforming the approach to chronic upper-airway dysfunction. By elucidating the pathways through which mechanical stimuli influence epithelial signaling, inflammation, and tissue remodeling, clinicians and researchers can better stratify risk, personalize therapy, and ultimately improve patient outcomes. Ongoing research into mechanosensory modulation and barrier restoration holds promise for the next generation of therapeutic interventions, with potential to reduce disease burden and enhance quality of life for affected individuals.